ADVANZ PHARMA UK AND IRELAND LIMITED
Get an alert when ADVANZ PHARMA UK AND IRELAND LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-10-14 (in 5mo)
Last made up 2025-09-30
Watchouts
None on the register
Cash
£4M
+115.3% vs 2023
Net assets
£5M
+1.4% highest in 3 filed years
Employees
11
-15.4% lowest in 3 filed years
Profit before tax
£527K
+17.5% vs 2023
Net assets
3-year trend · vs Consumer Discretionary median
Accounts
3-year trend · latest reflected 2024-12-31
| Metric | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Turnover | £12,207,278 | £14,121,158 | £17,983,676 | |
| Operating profit | £844,836 | £448,317 | £526,994 | |
| Profit before tax | £844,836 | £448,317 | £526,994 | |
| Net profit | — | £418,900 | £526,994 | |
| Cash | £6,847,604 | £1,830,868 | £3,942,577 | |
| Total assets less current liabilities | £5,839,343 | £7,014,686 | — | |
| Net assets | £4,693,657 | £5,112,557 | £5,183,328 | |
| Equity | £4,693,657 | £5,112,557 | £5,183,328 | |
| Average employees | 14 | 13 | 11 | |
| Wages | — | £1,796,220 | £1,193,529 | |
| Directors' remuneration | — | £371,818 | £218,378 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+27.4%
£14,121,158 £17,983,676
highest in 3 filed years
-
Cash
+115.3%
£1,830,868 £3,942,577
-
Net assets
+1.4%
£5,112,557 £5,183,328
highest in 3 filed years
-
Employees
-15.4%
13 11
lowest in 3 filed years
-
Operating profit
+17.5%
£448,317 £526,994
-
Profit before tax
+17.5%
£448,317 £526,994
-
Wages
-33.6%
£1,796,220 £1,193,529
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|
| Operating margin | 6.9% | 3.2% | 2.9% | |
| Net margin | — | 3.0% | 2.9% | |
| Return on capital employed | 14.5% | 6.4% | — | |
| Current ratio | — | 1.24x | 2.57x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ADVANZ PHARMA UK AND IRELAND LIMITED 2022-08-23 → present
- INTERCEPT PHARMA UK & IRELAND LTD 2015-09-24 → 2022-08-23
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Azets Audit Services Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realise its assets and discharge its liabilities in the normal course of operations as they come due. In assessing the ability of the Company to continue as a going concern, the directors have taken account of the profit in 2024 of £526,994, the cumulative profits of £453,326, and the Company's net current asset and net asset position of £7,293,394 and £5,183,328, respectively at 31 December 2024. The Company's Intermediate Holding Company, APHL, has provided the Company with a letter of support indicating its intention to provide any financial support required for a period of at least 12 months from the date these financial statements are approved. Considering the letter of support received from APHL, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the directors consider it appropriate to prepare these financial statements on a going concern basis.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 12 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ETTERY, Nicholas | Director | 2024-02-23 | Feb 1973 | British |
| FERRY, Melvin Jeremy, Mr. | Director | 2025-02-06 | Jun 1982 | British |
| TUCKER, Simon | Director | 2022-07-01 | Oct 1974 | British |
Show 12 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| QUAYSECO LIMITED | Corporate Secretary | 2015-09-24 | 2022-07-01 |
| BARCELO SANCHEZ, Francisco Javier | Director | 2022-07-01 | 2024-12-31 |
| DUNCAN, Barbara | Director | 2015-09-24 | 2017-10-01 |
| GEMELLARO, Michael | Director | 2021-05-20 | 2022-07-01 |
| HOOD, Daniel Carey Cazel | Director | 2015-09-24 | 2018-05-09 |
| KAMATH, Vikram Laxman | Director | 2022-07-01 | 2025-02-06 |
| KAPADIA, Sandip | Director | 2017-10-01 | 2021-03-26 |
| NOTARIANNI, Giancarlo | Director | 2017-12-31 | 2024-02-23 |
| SHARPE, Stewart Charles | Director | 2017-10-01 | 2017-12-31 |
| STOCKWELL, Caroline Amelia | Director | 2021-03-17 | 2021-10-29 |
| VAN WEPEREN, Willem Wouter | Director | 2021-10-04 | 2022-07-01 |
| VENEZIA, Rocco | Director | 2021-05-20 | 2022-07-01 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mercury Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-07-01 | Active |
| Intercept Pharmaceuticals, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2022-07-01 |
Filing timeline
Last 20 of 68 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-11-12 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-30 | AA | accounts | Accounts with accounts type full | |
| 2025-02-20 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-19 | TM01 | officers | Termination director company with name termination date | |
| 2025-01-08 | TM01 | officers | Termination director company with name termination date | |
| 2024-11-20 | AAMD | accounts | Accounts amended with accounts type full | |
| 2024-10-09 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-09-27 | AA | accounts | Accounts with accounts type total exemption full | |
| 2024-03-26 | AP01 | officers | Appoint person director company with name date | |
| 2024-03-06 | TM01 | officers | Termination director company with name termination date | |
| 2024-01-08 | AA | accounts | Accounts with accounts type full | |
| 2023-10-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-16 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2023-08-03 | CH01 | officers | Change person director company with change date | |
| 2023-08-03 | CH01 | officers | Change person director company with change date | |
| 2023-08-03 | CH01 | officers | Change person director company with change date | |
| 2023-08-02 | CH01 | officers | Change person director company with change date | |
| 2023-08-01 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-05-04 | AA | accounts | Accounts with accounts type full | |
| 2022-11-07 | CS01 | confirmation-statement | Confirmation statement with updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.